This study was designed to estimate the effect of time-released garlic powder tablets Allicor on the progression of carotid atherosclerosis in 211 asymptomatic men aged 40-74 in double-blinded placebo-controlled clinical trial. The primary outcome was the rate of atherosclerosis progression, measured by B-mode ultrasonography as the increase in carotid intima-media thickness (cIMT). In Allicor-treated group the decrease of cIMT by 0.028±0.008 mm was observed, whereas in placebo group there was a moderate progression at the rate of 0.014±0.009 mm per 12 months (P=0.002 for the difference). Serum atherogenicity (the ability of serum to induce cholesterol accumulation in cultured cells) was lowered in Allicor-treated patients by 45% from the baseline level, on an average. In the placebo group, serum atherogenic potential did not change significantly. These results demonstrate that long-term treatment with Allicor provides a direct antiatherosclerotic effect on subclinical carotid atherosclerosis, and this effect may be due to serum atherogenicity inhibition.
|Number of pages||10|
|Journal||Experimental and Clinical Cardiology|
|Publication status||Published - 2014|
- Intima-media thickness
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)